With Pfizer’s stock down sharply, an activist investor is pushing for CEO Albert Bourla to improve performance.

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

However, seasoned pharmaceutical investors recognize the industry's cyclical nature. The industry's rhythm of drug ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to shift.

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Pfizer (NYSE:PFE) with a Market Perform ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...